RSSCollection: Rensselaer Polytechnic Institute (RPI)
- Carl Weissman Concludes Accelerator Corp Is A Solution To Biotech Startup Investing
- Carl Weissman Discusses Accelerator Corp's Model Of Early Stage Biotect Startup Investment
- Carl Weissman Discusses Challenges Of Legal Issues Surrounding Formation of Accelerator And Accelerator VC Deals
- Carl Weissman Discusses Challenges of Risk and Effort In Biotech Startup Process
- Carl Weissman Discusses Consolidation in Venture Capital Arena
- Carl Weissman Discusses Financial Structure of Accelerator Corp.
- Carl Weissman Discusses Investment in DLST Startup
- Carl Weissman Discusses Investment in Homestead Clinical and Allozyne Startups
- Carl Weissman Discusses Investment in Spaltudaq Startup
- Carl Weissman Discusses Investment in VieVax Startup
- Carl Weissman Discusses Range in Valuations and Milestons Among Accelerator Deals
- Carl Weissman Discusses Shift In VC Funding Of Biotechs To Later Stage of Company Growth and Clinical Development
- Carl Weissman Discusses Sources of Deal Flow For Accelerator Corp
- Carl Weissman Discusses The Process of Doing An Accelerator Corp Deal
- Carl Weissman Discusses Valuation Process Used At Accelerator Corp
- Carl Weissman Outlines What Makes A Strong Candidate For Accelerator Corp Investment
- Carl Weissman Shaes Thoughts on Investing In Alternative Drug Delivery Technologies
- Carl Weissman States Accelerator Corp Is Trying To Solve Biotechnology Startup Problem
- Carl Weissman States Accelerator Corp Will Form and Run Biotech Startup Once Invested
- Christoph Hergersberg Discusses 'So What?' Aspect To Personalized Medicine
- Christoph Hergersberg Discusses Aspects of Monitoring
- Christoph Hergersberg Discusses Challenge of Getting Customer Feedback
- Christoph Hergersberg Discusses Challenge of Making Medicine More Cost Efficient
- Christoph Hergersberg Discusses Decision Making Aspect of Personalized Medicine
- Christoph Hergersberg Discusses Difficulty Of Making Decisions When It Comes To Early Ideas and Innovations
- Christoph Hergersberg Discusses Gap Between New Technology and Market Adoption
- Christoph Hergersberg Discusses GE's Efforts With Technology Related To Health Care Integration
- Christoph Hergersberg Discusses Impact of Information Technology on Medicine
- Christoph Hergersberg Discusses Importance of Connecting With Customers
- Christoph Hergersberg Discusses Importance of Developing Drugs That Respond TO Niche Market Needs But Also Have Potential To Extend
- Christoph Hergersberg Discusses Importance of Improving Ending Processes In Pharm Industry
- Christoph Hergersberg Discusses Importance of Targeted Populations
- Christoph Hergersberg Discusses Pharma Product Life Cycle
- Christoph Hergersberg Discusses R&D Strategy Within Pharmas
- Christoph Hergersberg Discusses Relationship Between Big Pharmas and Small Biotech Companies
- Christoph Hergersberg Discusses Technology Management and Importance of Knowing Where You Want To Go
- Christoph Hergersberg Shares Thoughts on Biomarkers
- Christoph Hergersberg Shares Thoughts on Blockbuster Drugs
- Christoph Hergersberg Shares Thoughts on Drug Efficacy
- Christoph Hergersberg Shares Thoughts on Immunotherapy
- Christoph Hergersberg Shares Thoughts on R&D Growth Rates in Pharma Industry
- Christoph Hergersberg States Importance of Carefully Selecting The Problem
- Christoph Hergersberg States Importance of Looking At Problem By Going Back To Biology
- Christoph Hergersberg States Pharmas Are Realizing That Clinical Understanding Of Disease Is Central To R&D
- Christoph Hergersberg States Pharmas Try To Pick The Best Targets
- Christoph Hergersberg States Reality of Huge Knowledge Base Within Pharma Companies
- David Weinstein Discovers Process of Discovering How Brain Tumors Can Be Turned Off
- David Weinstein Discusses Challenges of Financing Biotech Companies
- David Weinstein Discusses Decision To Leave Stable Academic Center And Start Company
- David Weinstein Discusses Guiding Princples For Running GliaMed
- David Weinstein Discusses Scientific Approach At GliaMed
- David Weinstein Provides Background on His Company, GliaMed
- David Weinstein Shares Thoughts on Conflict of University As Simultaneously Being Ivory Tower and Business
- David Weinstein States Business Model Focuses On Generating Revenue Stream To Fund Other Initiaitves
- David Weinstein States Challenge of Being A Scientist In the World of Business
- David Weinstein States Wound Care Drug Came From Failure From Other Clinical Experiment
- Matthew McCooe Discusses Decision To Link Faculty Members With Business Students To Assist With Business Plan Writing Process
- Matthew McCooe Discusses Handling Intellectual Property Licences With University-Based Startups
- Matthew McCooe Discusses How Technology Transfer Process Works
- Matthew McCooe Discusses Phases of Company Valuation And How Intellectual Property Is Rewarded
- Matthew McCooe Discusses Return on Investment For University Startups
- Matthew McCooe Discusses Role of Technology Transfer Within Universities
- Matthew McCooe Discusses Trend Among Universities To Finance Early Research Since VCs Are Becoming More Conservative
- Matthew McCooe States Many Universities Are Creating Seed Funds and Small VC Funds To Finance Early-Stage Research Projects
- Paul McManus Defines The Scientist-Founder Role
- Paul McManus Discusses Importance of Building Depth As Startup Grows
- Paul McManus Discusses Importance Of Business Development Process
- Paul McManus Discusses Importance of Managing Cash Flow and Growth of Startup
- Paul McManus Discusses Pathway That Startups Follow and States People Are Most Important Part of Business Plan
- Paul McManus Discusses Reasons Why VCs Will Not Invest
- Paul McManus Discusses Returns Within VC Company And Why Failures Occur
- Paul McManus Discusses Tech Transfer Process
- Paul McManus Discusses The Getting-To-Velocity Phase of Business Development
- Paul McManus Discusses The Infinity-And-Beyond Phase of Business Development Where You Enter Marketplace
- Paul McManus Outlines The Launch Phase of Starting A Business
- Paul McManus Outlines Three Business Development Models
- Paul McManus Provides Introduction To Lecture and States Most Important Aspect Of An Entrepreneur Is Ability To Get Stuff Done
- Paul McManus Provides Summary of Lecture On Life Sciences Business Development and VC Funding Relationship
- Paul McManus Shares Characteristics of Strong Entrepreneurs
- Paul McManus Shares Personality Traits Of Strong Entrepreneurs
- Paul McManus Shares Thoughts on Building The Organization Beyond The R&D Team
- Paul McManus States Entrepreneurs Are Decision Makers Who Stretch The Rules
- Paul McManus States Entrepreneurs Need More Patience When Requesting Funding
- Paul McManus States Entrepreneurs Need To Be Flexible and Learn To Close
- Paul McManus States Entrepreneurs Polarize People With Their Passion
- Paul McManus States Lack Of Strong Executives In Life Science Companies
- Paul McManus States Strong Entrepreneurs Can Focus On One Thing By Being Adaptive In Resource Allocation
- Paul McManus States VC Will Try To Determine Risks and Evaluate How Founding Team Will Handle Them
- Paul McManus States VCs Don't Invest In A Nice Looking Business Plan Or A Great Idea - They Invest In People
- Paul McManus States Venture Investors Are Evidence Oriented
- Peter Staudhammer Discusses Academic Freedom Versus Commercialization
- Peter Staudhammer Discusses Alignment With Graduate Busienss School To Assist With Project Evaluations
- Peter Staudhammer Discusses Balance of Power In Projects
- Peter Staudhammer Discusses Challenges of Handling IP At Universities
- Peter Staudhammer Discusses Commitment of Tenured Individual Versus Entrepreneur
- Peter Staudhammer Discusses Current Projects At Alfred Mann Institute
- Peter Staudhammer Discusses Distribution Of Funds
- Peter Staudhammer Discusses Establishment of Alfred Mann Institute
- Peter Staudhammer Discusses Freedom To Publish
- Peter Staudhammer Discusses Importance of Entrepreneurial Mindset Within Institute
- Peter Staudhammer Discusses Mistakes With First Project On Intubation
- Peter Staudhammer Discusses Opposition To Commercialization Within Academic Campus
- Peter Staudhammer Discusses Planning Involved In Decision Whether or Not To Pursue a Project
- Peter Staudhammer Discusses Process of Project Reviews and Decision To Pursue Or Reject Projects
- Peter Staudhammer Discusses Project Focus and Pace
- Peter Staudhammer Discusses Project Selection Process
- Peter Staudhammer Discusses Relationship Between Alfred Mann Institute and USC
- Peter Staudhammer Discussses Guidelines For Creation of Future Institutes
- Peter Staudhammer Provides Background of Alfred Mann
- Peter Staudhammer Shares Thoughts on Exit Strategies
- Peter Staudhammer States Alfred Mann Institute Has Been Able To Make Positive Impact On People' Lives
- Peter Staudhammer States Alfred Mann Institute Insists On Controlling Intellectual Property
- Peter Staudhammer States Importance of Betting On People
- Peter Staudhammer States Importance of Having Inventor's Cooperation
- Peter Staudhammer States Institue Does Not Award Grants - They Are Part of A Directed Commercialization Process
- Peter Staudhammer States Part of His Job Is To Answer To Capital Providers
- Peter Staudhammer States Projects Have Friction And Are Not Autocratic
- Peter Staudhammer States Rejected Projects Are Given Back To University Not To Inventors
- Robert Hallenbeck Discusses Challenges of Asset Allocation In Collaborative Arrangement
- Robert Hallenbeck Discusses Challenges of Exclusive License Agreements
- Robert Hallenbeck Outlines Example of First Meeting Of Small Company and Potential Investors
- Robert Hallenbeck Shares Examples of Agreements Between Small Companies and Venture Funders
- Robert Hallenbeck States Importance of Investors Maintaining Control of Company Directors
- Robert Hallenbeck States Importance of Trust In Strategic Relationships
- Robert Hallenbeck States In Most Situations Capital Is Given In Exchange For Rights
- Robert Hallenbeck States Negotiation Is About Understanding Wants and Needs
- Robert Hallenbeck States Small Companies Have To Do What Is Right To Keep Company In Business Rather Than Pinning Hopes On Big Deals
- Robert Hallenbeck States Venture Capital Does Not Come For Free
- Ted Hagelin Discusses Advent of Hatch Waxman Act Which Amended US Patent Act
- Ted Hagelin Discusses Case Which Determined Whether Hatch Waxman Covers Medical Devices
- Ted Hagelin Discusses Concept of Experimental Use Exemptions
- Ted Hagelin Discusses Difficulty in Exemptions Related To Research Tools
- Ted Hagelin Discusses Hatch-Waxman Act's Protection of General Research To Identify New Drugs
- Ted Hagelin Discusses Need For Licensing If Patented Material Is Part of New Product
- Ted Hagelin Discusses Reality of Unlicensed Use of Patented Technologies At Universities
- Ted Hagelin Discusses Regulation of Hybrid Technologies
- Ted Hagelin Discusses Reluctance of Government To Put Experimental Use Exemption Into Law
- Ted Hagelin Provides Definition of Reach Through Royalties
- Ted Hagelin Provides Overview of U.S. Patent System
- Ted Hagelin Shares Reevaluation of Cases When Research Tools Are Seen As Assays Instead of Drugs
- Ted Hagelin Shares Thoughts on How Exemption Statement Should Be Used
